Principal investigators and research institutions seeking to buy original CJC-1295 require verified chemical purity, precise structural identity, and reliable batch-to-batch consistency. PX1 Research provides USA-manufactured, analytical-grade GHRH analogs paired with lot-specific COAs for advanced preclinical in vitro and in vivo studies.
Principal investigators and research institutions seeking to buy original CJC-1295 require verified chemical purity, precise structural identity, and reliable batch-to-batch consistency. PX1 Research provides USA-manufactured, analytical-grade GHRH analogs paired with lot-specific COAs for advanced preclinical in vitro and in vivo studies.
To buy original CJC-1295 for laboratory research means procuring a high-purity, synthetically verified Growth Hormone-Releasing Hormone (GHRH) analog manufactured under strict quality standards. Original CJC-1295 (a modified 29-amino-acid sequence) targets anterior pituitary somatotrophs to elevate endogenous growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) levels in preclinical models of tissue repair, cellular regeneration, and metabolic signaling.
When sourcing research compounds for quantitative bioassays, procuring verified materials from documented suppliers prevents experimental skew caused by truncated peptides, residual trifluoroacetic acid (TFA), or bacterial endotoxins. Researchers evaluating original CJC-1295 must distinguish between the unmodified tetrasubstituted GRF 1-29 form and versions containing Drug Affinity Complex (DAC) technology to ensure accurate dosing protocols in receptor-binding models.
CJC-1295 is a synthetic derivative of natural growth hormone-releasing hormone (GHRH 1-29). The core sequence consists of 29 amino acids modified at four strategic positions (D-Ala2, Gln8, Ala15, and Leu27) to enhance enzymatic resistance against dipeptidyl peptidase IV (DPP-IV) degradation. This chemical substitution stabilizes the peptide chain without compromising its affinity for the GHRH receptor located on anterior pituitary somatotroph membranes.
In chemical literature, 'original CJC-1295' often refers to the core sequence without the maleimidopropionic acid linker (frequently designated as Modified GRF 1-29 or CJC-1295 No DAC). The presence or absence of the conjugate group alters the half-life profile significantly: non-conjugated forms exhibit a half-life of roughly 30 minutes in plasma assays, whereas conjugated DAC variants demonstrate extended serum stability lasting several days. Research teams can browse our comprehensive catalog of all peptides to select the exact molecular configuration demanded by their research protocols.
The primary biological role of CJC-1295 is acting as a selective GHRH receptor agonist. Upon binding to the GHRH-R G-protein coupled receptor complex on somatotroph cells, it initiates adenylate cyclase stimulation, triggering cyclic adenosine monophosphate (cAMP) accumulation and protein kinase A (PKA) activation. This signaling cascade promotes both the transcription of the growth hormone gene and the regulated exocytosis of stored GH vesicles.
Unlike direct recombinant GH administration, GHRH analogs preserve the native physiological feedback loop governed by somatostatin (SRIF). Preclinical studies suggest that CJC-1295 stimulates pulsatile or sustained GH release, which subsequently acts on hepatic receptors to upregulate endogenous synthesis of Insulin-like Growth Factor 1 (IGF-1). Detailed mechanism breakdowns are documented in our growth hormone secretagogues guide.
In animal models and cell culture models, CJC-1295 has been widely utilized to study tissue regeneration, nitrogen retention, and mitochondrial biogenesis. In rodent models of musculoskeletal injury, sustained elevation of the GH/IGF-1 axis via GHRH stimulation accelerates collagen deposition, satellite cell proliferation, and myotube hypertrophy in damaged skeletal muscle tissue.
Furthermore, in vitro data indicate that CJC-1295-mediated IGF-1 upregulation alters lipid metabolism by promoting lipolysis in adipocytes while conserving glycogen stores in cardiac and skeletal myocytes. Researchers investigating microvascular repair have also documented enhanced endothelial migration and cellular survival under ischemic stress conditions when exposed to sustained GHRH secretagogue signaling.
To select the proper secretagogue for a specific research model, investigators must evaluate how GHRH analogs compare to alternative secretagogue classes. While CJC-1295 works via the primary GHRH receptor, other compounds operate through distinct pathways such as the Ghrelin/Growth Hormone Secretagogue Receptor (GHS-R1a).
For instance, when evaluating GHRH class compounds, Tesamorelin features a trans-3-hexenoic acid modification tailored for visceral adiposity models, whereas Sermorelin represents the basic native 29-amino-acid sequence with a shorter half-life. Conversely, ghrelin mimetics like Ipamorelin act synergistically with GHRH analogs by stimulating GH release through separate cellular cascades without causing significant cortisol or prolactin spikes. A deeper breakdown of these distinct structural dynamics is detailed in our GHRH analogs technical overview.
When purchasing CJC-1295 for quantitative lab assays, verify that the material undergoes rigorous analytical validation. Impurities such as truncated peptide fragments, diastereomers, or organic solvent residues can distort binding kinetics, cell viability assays, and receptor affinity measurements.
Every lot of peptide produced for PX1 Research undergoes rigorous testing in an ISO 17025 accredited laboratory. Quality verification requires two primary analytical methodologies: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity above 99.0%, and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify the exact molecular mass (MW 3367.97 g/mol for Modified GRF 1-29). Researchers can inspect batch integrity through our publicly accessible research documentation hub.
For cell culture assays and sensitive animal research, bacterial endotoxins (lipopolysaccharides derived from Gram-negative bacterial cell walls) represent a major confounding variable. Excessive endotoxin levels cause pyrogenic responses, non-specific inflammatory cytokine release, and premature cell death in primary culture models.
PX1 Research enforces strict endotoxin screening using Chromogenic Reagent Kinetic LAL (Limulus Amebocyte Lysate) assays. Every batch is certified to contain <0.01 EU/mg, far below industry standards. Combined with synthesis in GMP-compliant domestic facilities, this level of purity ensures that observed biological activity is attributable solely to the peptide molecule.
Lyophilized CJC-1295 must be handled using standard aseptic laboratory techniques to ensure chemical stability. Reconstitution should be performed using sterile laboratory-grade solvents such as Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.1% acetic acid solution depending on the planned assay pH requirements.
To reconstitute, slowly inject the diluent down the glass vial side wall, avoiding vigorous agitation or vortexing which can cause shear-induced peptide denaturation or aggregation. Once dissolved, store aliquots at 2°C to 8°C for short-term evaluation (up to 30 days) or freeze at -20°C to -80°C for extended stability. Avoid repeated freeze-thaw cycles. Detailed storage parameters are provided with every order under our wholesale institutional procurement program.
PX1 Research is an established USA-based supplier dedicated exclusively to serving academic institutions, biotechnology enterprises, and clinical research facilities. We eliminate supply chain opacity by offering full transparency and verifiable analytical data for every lot in our inventory.
Key PX1 Research advantages include:
• 100% USA-Manufactured Compounds synthesized in ISO/GMP-compliant facilities.
• Lot-Specific Certificates of Analysis (COA) containing raw RP-HPLC chromatograms and mass spectra.
• Verified Purity (≥99.0%) with mandatory endotoxin quantification (<0.01 EU/mg).
• Rapid Same-Day Dispatch on orders placed Monday through Friday from our California and Arizona logistics hubs.
When your research requires uncompromised chemical fidelity, choose PX1 Research as your trusted domestic reagent source.
What is the structural difference between CJC-1295 with DAC and without DAC?
CJC-1295 without DAC (often called Modified GRF 1-29) consists of the modified 29-amino-acid chain with a half-life of roughly 30 minutes. CJC-1295 with DAC includes a maleimidopropionic acid linker that covalently binds to circulating serum albumin, extending its biological half-life to several days in animal models.
What purity level can I expect when I buy original CJC-1295 from PX1 Research?
All CJC-1295 batches supplied by PX1 Research are verified by RP-HPLC to meet or exceed 99.0% chemical purity. Every shipment includes a lot-specific Certificate of Analysis verifying identity and purity.
How is the exact molecular mass of CJC-1295 verified?
Molecular mass is verified using Electrospray Ionization Mass Spectrometry (ESI-MS) conducted by independent, ISO 17025 accredited testing laboratories.
What solvent should be used for reconstituting CJC-1295 in a lab setting?
Lyophilized CJC-1295 is typically reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS), depending on the requirements of your specific in vitro or in vivo assay.
What are the recommended laboratory storage conditions for CJC-1295?
Lyophilized vials should be stored at -20°C to -80°C in a desiccated environment. Reconstituted liquid solutions should be aliquoted and kept at 2°C to 8°C for short-term use, avoiding repeated freeze-thaw cycles.
Are PX1 Research compounds approved for human consumption?
No. All products sold by PX1 Research, including CJC-1295, are strictly intended for laboratory research and preclinical testing only. They are not for human or veterinary use, medical treatment, or diagnostic applications.
How does CJC-1295 compare to Sermorelin in research models?
Sermorelin represents the native amino acid sequence 1-29 of GHRH, which is rapidly degraded by DPP-IV enzymes. CJC-1295 contains four substituted amino acids that resist enzymatic cleavage, conferring greater plasma stability.
What is the endotoxin limit on research-grade CJC-1295 from PX1?
PX1 Research enforces strict endotoxin controls, certifying every lot to contain less than 0.01 EU/mg as measured by kinetic LAL testing.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.